{"publication_id":"ba51abd9-ce97-48b3-b9e2-eb5a53bbd780","traces":[{"claim_id":"claim_1","claim":"Across retrieved source-level receipts for empagliflozin, which endpoints show directionally favorable versus null/non-convergent signals, and what matched PICO remains untested?","candidate_sources":[{"source_id":"source_1","study":"Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis","doi":"10.1093/eurjpc/zwab173","url":"https://doi.org/10.1093/eurjpc/zwab173","support_kind":"candidate_source_row","population":"patients with T2DM and/or HF","endpoint":"not extracted","effect":"not extracted","directness":"review-level"},{"source_id":"source_2","study":"Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment","doi":"10.1161/jaha.119.015716","url":"https://doi.org/10.1161/jaha.119.015716","support_kind":"candidate_source_row","population":"patients with type 2 diabetes mellitus","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_3","study":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","doi":"10.1161/circulationaha.116.021887","url":"https://doi.org/10.1161/circulationaha.116.021887","support_kind":"candidate_source_row","population":"patients with type 2 diabetes mellitus and established cardiovascular disease","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_4","study":"Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials","doi":"10.2174/1573399812666160613113556","url":"https://doi.org/10.2174/1573399812666160613113556","support_kind":"candidate_source_row","population":"patients with T2DM and increased cardiovascular risk","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_5","study":"EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors","doi":"10.1093/ckj/sfad082","url":"https://doi.org/10.1093/ckj/sfad082","support_kind":"candidate_source_row","population":"CKD patients based on eGFR slopes","endpoint":"not extracted","effect":"not extracted","directness":"primary"}]},{"claim_id":"claim_2","claim":"Finding: SGLT-2i showed a greater decrease of PWV (10.1%) than insulin or GLP-1RA.","candidate_sources":[{"source_id":"source_1","study":"Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis","doi":"10.1093/eurjpc/zwab173","url":"https://doi.org/10.1093/eurjpc/zwab173","support_kind":"candidate_source_row","population":"patients with T2DM and/or HF","endpoint":"not extracted","effect":"not extracted","directness":"review-level"},{"source_id":"source_2","study":"Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment","doi":"10.1161/jaha.119.015716","url":"https://doi.org/10.1161/jaha.119.015716","support_kind":"candidate_source_row","population":"patients with type 2 diabetes mellitus","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_3","study":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","doi":"10.1161/circulationaha.116.021887","url":"https://doi.org/10.1161/circulationaha.116.021887","support_kind":"candidate_source_row","population":"patients with type 2 diabetes mellitus and established cardiovascular disease","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_4","study":"Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials","doi":"10.2174/1573399812666160613113556","url":"https://doi.org/10.2174/1573399812666160613113556","support_kind":"candidate_source_row","population":"patients with T2DM and increased cardiovascular risk","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_5","study":"EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors","doi":"10.1093/ckj/sfad082","url":"https://doi.org/10.1093/ckj/sfad082","support_kind":"candidate_source_row","population":"CKD patients based on eGFR slopes","endpoint":"not extracted","effect":"not extracted","directness":"primary"}]},{"claim_id":"claim_3","claim":"| Outcome family | Receipt | Evidence role | Population/setting | Metric | Extracted finding |","candidate_sources":[{"source_id":"source_1","study":"Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis","doi":"10.1093/eurjpc/zwab173","url":"https://doi.org/10.1093/eurjpc/zwab173","support_kind":"candidate_source_row","population":"patients with T2DM and/or HF","endpoint":"not extracted","effect":"not extracted","directness":"review-level"},{"source_id":"source_2","study":"Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment","doi":"10.1161/jaha.119.015716","url":"https://doi.org/10.1161/jaha.119.015716","support_kind":"candidate_source_row","population":"patients with type 2 diabetes mellitus","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_3","study":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","doi":"10.1161/circulationaha.116.021887","url":"https://doi.org/10.1161/circulationaha.116.021887","support_kind":"candidate_source_row","population":"patients with type 2 diabetes mellitus and established cardiovascular disease","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_4","study":"Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials","doi":"10.2174/1573399812666160613113556","url":"https://doi.org/10.2174/1573399812666160613113556","support_kind":"candidate_source_row","population":"patients with T2DM and increased cardiovascular risk","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_5","study":"EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors","doi":"10.1093/ckj/sfad082","url":"https://doi.org/10.1093/ckj/sfad082","support_kind":"candidate_source_row","population":"CKD patients based on eGFR slopes","endpoint":"not extracted","effect":"not extracted","directness":"primary"}]},{"claim_id":"claim_4","claim":"| outcome-specific | Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose... | directionally favorable | patients with type 2 diabetes mellitus | - | SGLT-2i showed a greater decrease of PWV (10.1%) than insulin or GLP-1RA |","candidate_sources":[{"source_id":"source_1","study":"Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis","doi":"10.1093/eurjpc/zwab173","url":"https://doi.org/10.1093/eurjpc/zwab173","support_kind":"candidate_source_row","population":"patients with T2DM and/or HF","endpoint":"not extracted","effect":"not extracted","directness":"review-level"},{"source_id":"source_2","study":"Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment","doi":"10.1161/jaha.119.015716","url":"https://doi.org/10.1161/jaha.119.015716","support_kind":"candidate_source_row","population":"patients with type 2 diabetes mellitus","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_3","study":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","doi":"10.1161/circulationaha.116.021887","url":"https://doi.org/10.1161/circulationaha.116.021887","support_kind":"candidate_source_row","population":"patients with type 2 diabetes mellitus and established cardiovascular disease","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_4","study":"Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials","doi":"10.2174/1573399812666160613113556","url":"https://doi.org/10.2174/1573399812666160613113556","support_kind":"candidate_source_row","population":"patients with T2DM and increased cardiovascular risk","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_5","study":"EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors","doi":"10.1093/ckj/sfad082","url":"https://doi.org/10.1093/ckj/sfad082","support_kind":"candidate_source_row","population":"CKD patients based on eGFR slopes","endpoint":"not extracted","effect":"not extracted","directness":"primary"}]},{"claim_id":"claim_5","claim":"| outcome-specific | Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3... | directionally favorable | patients with T2DM and increased cardiovascular... | - | relative risk reductions in major adverse cardiac events (14%) |","candidate_sources":[{"source_id":"source_1","study":"Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis","doi":"10.1093/eurjpc/zwab173","url":"https://doi.org/10.1093/eurjpc/zwab173","support_kind":"candidate_source_row","population":"patients with T2DM and/or HF","endpoint":"not extracted","effect":"not extracted","directness":"review-level"},{"source_id":"source_2","study":"Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment","doi":"10.1161/jaha.119.015716","url":"https://doi.org/10.1161/jaha.119.015716","support_kind":"candidate_source_row","population":"patients with type 2 diabetes mellitus","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_3","study":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","doi":"10.1161/circulationaha.116.021887","url":"https://doi.org/10.1161/circulationaha.116.021887","support_kind":"candidate_source_row","population":"patients with type 2 diabetes mellitus and established cardiovascular disease","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_4","study":"Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials","doi":"10.2174/1573399812666160613113556","url":"https://doi.org/10.2174/1573399812666160613113556","support_kind":"candidate_source_row","population":"patients with T2DM and increased cardiovascular risk","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_5","study":"EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors","doi":"10.1093/ckj/sfad082","url":"https://doi.org/10.1093/ckj/sfad082","support_kind":"candidate_source_row","population":"CKD patients based on eGFR slopes","endpoint":"not extracted","effect":"not extracted","directness":"primary"}]},{"claim_id":"claim_6","claim":"This receipt-backed scoping note has one bounded signal: empagliflozin shows directionally consistent signals across heterogeneous contexts across this 5-source primary/review bundle (2016-2023). Evidence role grouping: direction-bearing receipts: 5; null/mixed metric-scope caveat receipts: 0. The source facts cover 5 population/setting context(s) and 2 intervention/exposure context(s), so this is a scoping signal about where endpoints diverge, without establishing a causal, clinical, species-translated, or mechanistically integrated claim. Direction is homogeneous: all selected receipts are directionally favorable. The boundary is population, comparator, and endpoint diversity, not directional disagreement. The listed effect sizes remain source-specific across endpoints and populations; they are not pooled or averaged. This is a heterogeneous indication/context map, not a unified disease-specific or endpoint-family claim.","candidate_sources":[{"source_id":"source_1","study":"Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis","doi":"10.1093/eurjpc/zwab173","url":"https://doi.org/10.1093/eurjpc/zwab173","support_kind":"candidate_source_row","population":"patients with T2DM and/or HF","endpoint":"not extracted","effect":"not extracted","directness":"review-level"},{"source_id":"source_2","study":"Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment","doi":"10.1161/jaha.119.015716","url":"https://doi.org/10.1161/jaha.119.015716","support_kind":"candidate_source_row","population":"patients with type 2 diabetes mellitus","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_3","study":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","doi":"10.1161/circulationaha.116.021887","url":"https://doi.org/10.1161/circulationaha.116.021887","support_kind":"candidate_source_row","population":"patients with type 2 diabetes mellitus and established cardiovascular disease","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_4","study":"Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials","doi":"10.2174/1573399812666160613113556","url":"https://doi.org/10.2174/1573399812666160613113556","support_kind":"candidate_source_row","population":"patients with T2DM and increased cardiovascular risk","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_5","study":"EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors","doi":"10.1093/ckj/sfad082","url":"https://doi.org/10.1093/ckj/sfad082","support_kind":"candidate_source_row","population":"CKD patients based on eGFR slopes","endpoint":"not extracted","effect":"not extracted","directness":"primary"}]},{"claim_id":"claim_7","claim":"null/non-convergent or other/mixed: the extracted fact is null, mixed, or not directionally interpretable.","candidate_sources":[{"source_id":"source_1","study":"Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis","doi":"10.1093/eurjpc/zwab173","url":"https://doi.org/10.1093/eurjpc/zwab173","support_kind":"candidate_source_row","population":"patients with T2DM and/or HF","endpoint":"not extracted","effect":"not extracted","directness":"review-level"},{"source_id":"source_2","study":"Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment","doi":"10.1161/jaha.119.015716","url":"https://doi.org/10.1161/jaha.119.015716","support_kind":"candidate_source_row","population":"patients with type 2 diabetes mellitus","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_3","study":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","doi":"10.1161/circulationaha.116.021887","url":"https://doi.org/10.1161/circulationaha.116.021887","support_kind":"candidate_source_row","population":"patients with type 2 diabetes mellitus and established cardiovascular disease","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_4","study":"Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials","doi":"10.2174/1573399812666160613113556","url":"https://doi.org/10.2174/1573399812666160613113556","support_kind":"candidate_source_row","population":"patients with T2DM and increased cardiovascular risk","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_5","study":"EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors","doi":"10.1093/ckj/sfad082","url":"https://doi.org/10.1093/ckj/sfad082","support_kind":"candidate_source_row","population":"CKD patients based on eGFR slopes","endpoint":"not extracted","effect":"not extracted","directness":"primary"}]},{"claim_id":"claim_8","claim":"directionally favorable: Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment — SGLT-2i showed a greater decrease of PWV (10.1%) than insulin or GLP-1RA.","candidate_sources":[{"source_id":"source_1","study":"Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis","doi":"10.1093/eurjpc/zwab173","url":"https://doi.org/10.1093/eurjpc/zwab173","support_kind":"candidate_source_row","population":"patients with T2DM and/or HF","endpoint":"not extracted","effect":"not extracted","directness":"review-level"},{"source_id":"source_2","study":"Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment","doi":"10.1161/jaha.119.015716","url":"https://doi.org/10.1161/jaha.119.015716","support_kind":"candidate_source_row","population":"patients with type 2 diabetes mellitus","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_3","study":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","doi":"10.1161/circulationaha.116.021887","url":"https://doi.org/10.1161/circulationaha.116.021887","support_kind":"candidate_source_row","population":"patients with type 2 diabetes mellitus and established cardiovascular disease","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_4","study":"Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials","doi":"10.2174/1573399812666160613113556","url":"https://doi.org/10.2174/1573399812666160613113556","support_kind":"candidate_source_row","population":"patients with T2DM and increased cardiovascular risk","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_5","study":"EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors","doi":"10.1093/ckj/sfad082","url":"https://doi.org/10.1093/ckj/sfad082","support_kind":"candidate_source_row","population":"CKD patients based on eGFR slopes","endpoint":"not extracted","effect":"not extracted","directness":"primary"}]},{"claim_id":"claim_9","claim":"directionally favorable: Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials — relative risk reductions in major adverse cardiac events (14%)","candidate_sources":[{"source_id":"source_1","study":"Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis","doi":"10.1093/eurjpc/zwab173","url":"https://doi.org/10.1093/eurjpc/zwab173","support_kind":"candidate_source_row","population":"patients with T2DM and/or HF","endpoint":"not extracted","effect":"not extracted","directness":"review-level"},{"source_id":"source_2","study":"Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment","doi":"10.1161/jaha.119.015716","url":"https://doi.org/10.1161/jaha.119.015716","support_kind":"candidate_source_row","population":"patients with type 2 diabetes mellitus","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_3","study":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","doi":"10.1161/circulationaha.116.021887","url":"https://doi.org/10.1161/circulationaha.116.021887","support_kind":"candidate_source_row","population":"patients with type 2 diabetes mellitus and established cardiovascular disease","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_4","study":"Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials","doi":"10.2174/1573399812666160613113556","url":"https://doi.org/10.2174/1573399812666160613113556","support_kind":"candidate_source_row","population":"patients with T2DM and increased cardiovascular risk","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_5","study":"EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors","doi":"10.1093/ckj/sfad082","url":"https://doi.org/10.1093/ckj/sfad082","support_kind":"candidate_source_row","population":"CKD patients based on eGFR slopes","endpoint":"not extracted","effect":"not extracted","directness":"primary"}]},{"claim_id":"claim_10","claim":"Evidence role summary: direction-bearing receipts: 5; null/mixed metric-scope caveat receipts: 0.","candidate_sources":[{"source_id":"source_1","study":"Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis","doi":"10.1093/eurjpc/zwab173","url":"https://doi.org/10.1093/eurjpc/zwab173","support_kind":"candidate_source_row","population":"patients with T2DM and/or HF","endpoint":"not extracted","effect":"not extracted","directness":"review-level"},{"source_id":"source_2","study":"Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment","doi":"10.1161/jaha.119.015716","url":"https://doi.org/10.1161/jaha.119.015716","support_kind":"candidate_source_row","population":"patients with type 2 diabetes mellitus","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_3","study":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","doi":"10.1161/circulationaha.116.021887","url":"https://doi.org/10.1161/circulationaha.116.021887","support_kind":"candidate_source_row","population":"patients with type 2 diabetes mellitus and established cardiovascular disease","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_4","study":"Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials","doi":"10.2174/1573399812666160613113556","url":"https://doi.org/10.2174/1573399812666160613113556","support_kind":"candidate_source_row","population":"patients with T2DM and increased cardiovascular risk","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_5","study":"EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors","doi":"10.1093/ckj/sfad082","url":"https://doi.org/10.1093/ckj/sfad082","support_kind":"candidate_source_row","population":"CKD patients based on eGFR slopes","endpoint":"not extracted","effect":"not extracted","directness":"primary"}]},{"claim_id":"claim_11","claim":"Specific moderators in this bundle are population/indication (CKD patients based on eGFR slopes; patients with T2DM and increased cardiovascular risk; patients with T2DM and/or HF; patients with type 2 diabetes mellitus; patients with type 2 diabetes mellitus and established cardiovascular disease), study design/evidence type (primary/review). Single primary-study estimates are separated from pooled review or meta-analytic estimates rather than treated as interchangeable.","candidate_sources":[{"source_id":"source_1","study":"Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis","doi":"10.1093/eurjpc/zwab173","url":"https://doi.org/10.1093/eurjpc/zwab173","support_kind":"candidate_source_row","population":"patients with T2DM and/or HF","endpoint":"not extracted","effect":"not extracted","directness":"review-level"},{"source_id":"source_2","study":"Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment","doi":"10.1161/jaha.119.015716","url":"https://doi.org/10.1161/jaha.119.015716","support_kind":"candidate_source_row","population":"patients with type 2 diabetes mellitus","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_3","study":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","doi":"10.1161/circulationaha.116.021887","url":"https://doi.org/10.1161/circulationaha.116.021887","support_kind":"candidate_source_row","population":"patients with type 2 diabetes mellitus and established cardiovascular disease","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_4","study":"Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials","doi":"10.2174/1573399812666160613113556","url":"https://doi.org/10.2174/1573399812666160613113556","support_kind":"candidate_source_row","population":"patients with T2DM and increased cardiovascular risk","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_5","study":"EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors","doi":"10.1093/ckj/sfad082","url":"https://doi.org/10.1093/ckj/sfad082","support_kind":"candidate_source_row","population":"CKD patients based on eGFR slopes","endpoint":"not extracted","effect":"not extracted","directness":"primary"}]},{"claim_id":"claim_12","claim":"Population/settings are separated as receipt context: CKD patients based on eGFR slopes, patients with T2DM and increased cardiovascular risk, patients with T2DM and/or HF, patients with type 2 diabetes mellitus, and patients with type 2 diabetes mellitus and established cardiovascular disease. The selected receipts group because each carries a fact-level extraction for empagliflozin; they separate by context (human clinical/observational) and endpoint, so they are not interchangeable evidence for one pooled claim.","candidate_sources":[{"source_id":"source_1","study":"Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis","doi":"10.1093/eurjpc/zwab173","url":"https://doi.org/10.1093/eurjpc/zwab173","support_kind":"candidate_source_row","population":"patients with T2DM and/or HF","endpoint":"not extracted","effect":"not extracted","directness":"review-level"},{"source_id":"source_2","study":"Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment","doi":"10.1161/jaha.119.015716","url":"https://doi.org/10.1161/jaha.119.015716","support_kind":"candidate_source_row","population":"patients with type 2 diabetes mellitus","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_3","study":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","doi":"10.1161/circulationaha.116.021887","url":"https://doi.org/10.1161/circulationaha.116.021887","support_kind":"candidate_source_row","population":"patients with type 2 diabetes mellitus and established cardiovascular disease","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_4","study":"Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials","doi":"10.2174/1573399812666160613113556","url":"https://doi.org/10.2174/1573399812666160613113556","support_kind":"candidate_source_row","population":"patients with T2DM and increased cardiovascular risk","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_5","study":"EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors","doi":"10.1093/ckj/sfad082","url":"https://doi.org/10.1093/ckj/sfad082","support_kind":"candidate_source_row","population":"CKD patients based on eGFR slopes","endpoint":"not extracted","effect":"not extracted","directness":"primary"}]},{"claim_id":"claim_13","claim":"The signal is purely descriptive of source-level direction and scope; it cannot support even a weak causal or comparative-efficacy inference, and pooling across these PICOs would be inappropriate.","candidate_sources":[{"source_id":"source_1","study":"Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis","doi":"10.1093/eurjpc/zwab173","url":"https://doi.org/10.1093/eurjpc/zwab173","support_kind":"candidate_source_row","population":"patients with T2DM and/or HF","endpoint":"not extracted","effect":"not extracted","directness":"review-level"},{"source_id":"source_2","study":"Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment","doi":"10.1161/jaha.119.015716","url":"https://doi.org/10.1161/jaha.119.015716","support_kind":"candidate_source_row","population":"patients with type 2 diabetes mellitus","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_3","study":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","doi":"10.1161/circulationaha.116.021887","url":"https://doi.org/10.1161/circulationaha.116.021887","support_kind":"candidate_source_row","population":"patients with type 2 diabetes mellitus and established cardiovascular disease","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_4","study":"Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials","doi":"10.2174/1573399812666160613113556","url":"https://doi.org/10.2174/1573399812666160613113556","support_kind":"candidate_source_row","population":"patients with T2DM and increased cardiovascular risk","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_5","study":"EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors","doi":"10.1093/ckj/sfad082","url":"https://doi.org/10.1093/ckj/sfad082","support_kind":"candidate_source_row","population":"CKD patients based on eGFR slopes","endpoint":"not extracted","effect":"not extracted","directness":"primary"}]}]}